ELI 002
Alternative Names: AMP KRAS; AMP-CpG; Amph-CpG-7909; Amphiphile mKRAS vaccine; Amphiphile-CpG; ELI-002; ELI-002 2P; ELI-002 7P; VED-002Latest Information Update: 03 Jul 2024
At a glance
- Originator Elicio Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Jun 2024 Updated efficacy data from a phase I/II in solid tumours released by Elicio Therapeutics
- 31 May 2024 Pharmacodynamics and adverse events data from phase I/II trial for Pancreatic cancer, Colorectal cancer and Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2024 Preliminary efficacy and adverse events data from the phase I/II AMPLIFY-7P trial in Solid tumours released by Elicio Therapeutics